345.2 Adverse effects of graft congestion and ameliorative effects of hepatocyte growth factor after liver transplantation in rats
Dr. Hikaru Aoki, Japan
345.3 Immunoisolation and islet survival in the absence of systemic immune suppression enabled by co-delivery of CXCL12 and FasL containing microgels in allo-islet transplanted diabetic mice
Dr. Fatma Dogan, United States
345.4 Long term results of de novo kidney transplant recipients treated with the combination of low dose Tacrolimus and Everolimus.
Ms. Franco Citterio, Italy
345.5 Alpha-1 antitrypsin-loaded nanoparticles improve transplantation outcomes in an acute liver failure rat model
Dr. Giuseppe Pettinato, United States
345.6 Systemic treatment with a novel form of FasL induces tolerance to cardiac allograft in mice
Dr. Feng Wang, People's Republic of China
345.7 Lactate remodulates the OXPHOS of Tregs by inducing N-glycosylation in mitochondria via transcription and translocation of MGAT1
Dr. Jinren Zhou, People's Republic of China
345.8 Normothermic Machine Perfusion of Explanted Livers: Pilot of a Novel Translational Model for End-Stage Liver Disease
Ms. Rachel Todd, United States
345.9 The mechanism research of intrahepatic glutamine metabolism promoting the differentiation of GARP Tregs to reshape the immune tolerance microenvironment post liver transplantation